Key result
Altered T-cell states follow aortic dissection, but targeting the IL-6–STAT3–IL-17 axis lacks therapeutic support.
Answers are grounded in this paper and cite their sources.
While single-cell and TCR profiling reveal altered T-cell states after aortic dissection onset, causal evidence is lacking, and research should prioritize biomarker validation and post-lesion mechanistic studies over early acute immunomodulation.
Single-cell RNA sequencing and T-cell receptor profiling reveal substantial T-cell heterogeneity in aortic dissection (AD), but whether these responses contribute to vascular injury or reflect post-onset immune activation remains uncertain. This review evaluates human and experimental evidence by disease stage, tissue compartment, functional validation, T-cell specificity, and intervention timing, distinguishing descriptive profiling from evidence supporting causal and translational inference. Human studies identify Th1/Th17-associated, CD8+ cytotoxicity-associated, and regulatory T-cell alterations, with stage-related differences in T-cell composition and clonality. Most evidence is cross-sectional and obtained after clinical onset. Antigen specificity, direct aortic-wall cytotoxicity, impaired Treg suppression, and T-cell-mediated aortic-wall injury remain unproven. Single-cell and TCR profiling identify candidate T-cell states and clonotypes for spatial and functional validation, not causal proof. Among candidate pathways, the IL-6–STAT3–IL-17 axis currently has the strongest AD-specific preclinical rationale, but existing interventions are largely non-T-cell-restricted and initiated before or during disease induction. Stronger causal attribution requires convergent human evidence, post-lesion T-cell-restricted perturbation, disease-progression endpoints, and rescue or target-engagement studies. The subacute phase after anatomical and haemodynamic stabilisation may offer a window to study persistent injury-amplifying T-cell responses, whereas early acute and perioperative immunomodulation remains unsupported. Current evidence supports altered T-cell states after AD onset but does not establish an initiating role. Near-term priorities should be prospective biomarker validation and post-lesion mechanistic studies rather than T-cell-directed immunomodulation during the early acute and perioperative phases. Clinical translation should await reproducible associations linked to stage-specific causal mechanisms and acceptable safety.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) conducted a review in Aortic dissection. T-cell immune profiling and IL-6–STAT3–IL-17 axis modulation was evaluated. T-cell states are altered after aortic dissection onset, particularly along the IL-6–STAT3–IL-17 axis, but causal initiating roles and acute immunomodulation remain unsupported.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: